Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132133 | 0.86 | MEN1 (0.47) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL4780472 | 0.83 | GPR84 (0.54) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL31756884 | 0.83 | GPR84 (0.54) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL28296648 | 0.78 | GPR84 (0.50) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL2533194 | 0.78 | MEN1 (0.56) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL16860069 | 0.78 | GPR84 (0.50) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL300507 | 0.78 | ALOX5 (0.57) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL29362847 | 0.78 | ALOX5 (0.57) | GPR84MEN1KMT2AKDM4EALOX5 | |
| Bromide SCHEMBL5880686 | 0.76 | ALOX5 (0.55) | GPR84MEN1KMT2AKDM4EALOX5 | |
| SCHEMBL5851578 | 0.76 | ALDH1A1 (0.63) | GPR84MEN1KMT2AKDM4EALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563739-B2 | Ruthenium complexes having hybrid amine ligands, their preparation and use | ENANTIOTECH CORPORATION LIMITED (CN) | 2013-10-22 | — | — | US | disclosed |
| EP-2294075-B1 | NOVEL RUTHENIUM COMPLEXES HAVING HYBRID AMINE LIGANDS, THEIR PREPARATION AND USE | ENANTIOTECH CORP LTD (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-20110092712-A1 | Novel Ruthenium Complexes Having Hybrid Amine Ligands, Their Preparation And Use | ENANTIOTECH CORPORATION LIMITED (CN) | 2011-04-21 | — | — | US | disclosed |
| EP-2294075-A1 | NOVEL RUTHENIUM COMPLEXES HAVING HYBRID AMINE LIGANDS, THEIR PREPARATION AND USE | Enantiotech Corporation Limited (CN) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009149670-A1 | NOVEL RUTHENIUM COMPLEXES HAVING HYBRID AMINE LIGANDS, THEIR PREPARATION AND USE | ENANTIOTECH CORPORATION LIMITED (CN) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092712-A1 | Novel Ruthenium Complexes Having Hybrid Amine Ligands, Their Preparation And Use | ADH5, ADH1C, ADH1A | GPR84 1019/4885MEN1 2486/4885KMT2A 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.